FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003758966> ?p ?o ?g. }

• W2003758966 endingPage "899" @default.
• W2003758966 startingPage "899" @default.
• W2003758966 abstract "The Authors Reply: — We thank Drs. Grant and Baca for their thoughtful comments on our article,1 and welcome the opportunity to respond to the assertion that there is little that can be done to manage risks associated with methadone prescribing in pain settings. In particular, the view that we overstate the ability to reduce risks appears overly pessimistic, may worsen methadone stigma, and is inconsistent with available data.In order to elaborate on this point we review a study2 examining the safety of using methadone in a Canadian pain clinic. A nurse management model enhanced monitoring of methadone use in 75 patients. The program consisted of three phases over 9 months: (a) a face to face educational session, (b) telephone calls during methadone titration, and (c) maintenance. Education focused on methadone pharmacology. Initial calls occurred 1 to 5 days later for close monitoring during initial treatment. For the titration and maintenance phases a questionnaire including reason for call, methadone dose, pain levels, activity levels, side effects and satisfaction with methadone was administered. Of 194 calls, 44% resulted in a methadone increase, and 11% led to methadone reduction or cessation. Over half the patients (57%) were either satisfied or very satisfied with methadone, and 8% stopped taking methadone due to efficacy or tolerability problems. No one developed significant morbidity or mortality. This study implies that there may a place for methadone in the treatment of pain. Indeed, in Canada, methadone is often used as first line or second-line analgesic.2 In the US there has been an effort to recognize situations where methadone analgesia offers advantage.3 Thus far, it appears that patients who have long-standing severe pain with a significant neuropathic component and who do not respond to other opioids may be suitable candidates. Such patients typically have tried and failed multiple agents which provided inadequate relief or intractable side effects. Methadone may also offer benefits in patients with renal dysfunction. It differs from other opiates in that it has NMDA receptor antagonism. Blocking the NMDA may provide additional pain reducing properties over typical opiates and may attenuate the process of developing opioid tolerance.3We agree with Drs. Grant and Baca that costs alone should not be driving medication considerations. Nevertheless, there appears to remain a role of methadone in the treatment of chronic pain.4 More research and improved physician education and prescription practice guidelines may help elucidate this role." @default.
• W2003758966 created "2016-06-24" @default.
• W2003758966 creator A5003915145 @default.
• W2003758966 creator A5085905942 @default.
• W2003758966 date "2010-06-08" @default.
• W2003758966 modified "2023-10-16" @default.
• W2003758966 title "Methadone Deaths in Pain and Addiction Populations" @default.
• W2003758966 cites W1989611146 @default.
• W2003758966 cites W1990700372 @default.
• W2003758966 cites W2062481213 @default.
• W2003758966 doi "https://doi.org/10.1007/s11606-010-1410-1" @default.
• W2003758966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2917662" @default.
• W2003758966 hasPublicationYear "2010" @default.
• W2003758966 type Work @default.
• W2003758966 sameAs 2003758966 @default.
• W2003758966 citedByCount "1" @default.
• W2003758966 crossrefType "journal-article" @default.
• W2003758966 hasAuthorship W2003758966A5003915145 @default.
• W2003758966 hasAuthorship W2003758966A5085905942 @default.
• W2003758966 hasBestOaLocation W20037589661 @default.
• W2003758966 hasConcept C118552586 @default.
• W2003758966 hasConcept C126322002 @default.
• W2003758966 hasConcept C170493617 @default.
• W2003758966 hasConcept C2777170798 @default.
• W2003758966 hasConcept C2778767360 @default.
• W2003758966 hasConcept C2781063702 @default.
• W2003758966 hasConcept C2909816603 @default.
• W2003758966 hasConcept C48856860 @default.
• W2003758966 hasConcept C71924100 @default.
• W2003758966 hasConceptScore W2003758966C118552586 @default.
• W2003758966 hasConceptScore W2003758966C126322002 @default.
• W2003758966 hasConceptScore W2003758966C170493617 @default.
• W2003758966 hasConceptScore W2003758966C2777170798 @default.
• W2003758966 hasConceptScore W2003758966C2778767360 @default.
• W2003758966 hasConceptScore W2003758966C2781063702 @default.
• W2003758966 hasConceptScore W2003758966C2909816603 @default.
• W2003758966 hasConceptScore W2003758966C48856860 @default.
• W2003758966 hasConceptScore W2003758966C71924100 @default.
• W2003758966 hasIssue "9" @default.
• W2003758966 hasLocation W20037589661 @default.
• W2003758966 hasLocation W20037589662 @default.
• W2003758966 hasOpenAccess W2003758966 @default.
• W2003758966 hasPrimaryLocation W20037589661 @default.
• W2003758966 hasRelatedWork W110093435 @default.
• W2003758966 hasRelatedWork W2023514949 @default.
• W2003758966 hasRelatedWork W2024502785 @default.
• W2003758966 hasRelatedWork W2027642205 @default.
• W2003758966 hasRelatedWork W2031359817 @default.
• W2003758966 hasRelatedWork W2058947309 @default.
• W2003758966 hasRelatedWork W2910538915 @default.
• W2003758966 hasRelatedWork W2915268315 @default.
• W2003758966 hasRelatedWork W2948417659 @default.
• W2003758966 hasRelatedWork W39317379 @default.
• W2003758966 hasVolume "25" @default.
• W2003758966 isParatext "false" @default.
• W2003758966 isRetracted "false" @default.
• W2003758966 magId "2003758966" @default.
• W2003758966 workType "article" @default.